Stealth BioTherapeutics Announces Positive Data on Mitochondria-based Therapy Ocuvia for Diabetic Macular Edema
Stealth BioTherapeutics, a privately held biopharmaceutical company committed to developing mitochondrial therapies to treat both common and rare diseases, recently announced data from its ReVIEW clinical trial of Ocuvia in patients with diabetic macular edema (DME). The data was recently presented during Stealth’s second Mitochondrial Science and Medicine Series symposium, which took place in…